40%–60% of systemic lupus erythematosus (SLE) patients develop lupus nephritis (LN) and identifying these individuals remains a significant clinical challenge with profound implications for morbidity, mortality and healthcare burden. Currently LN is diagnosed by invasive kidney biopsy, which is difficult to repeat to monitor disease activity. Prior studies have shown that IgG glycosylation is a robust biomarker of differentiating kidney involvement in SLE.